China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD 322 million) through a private placement. The proceeds will be used for the Shanghai biomedicine research and development (R&D) innovation industry base program, drug discovery and pharmaceutical research and filing platform laboratory expansion program, and supplementary working capital.
Company Overview
Medicilon, founded in 2004, is a Contract Research Organization (CRO) that provides global clients with pre – clinical animal study services. The company’s offerings cover a wide range of services, including lead compound screening, optimization, API preparation, formulation process development, and pharmacodynamics research. It also conducts preclinical pharmacokinetics and drug safety evaluation, focusing on the immune – oncology, antibody, and antibody drug conjugate (ADC) fields.-Fineline Info & Tech
